Y. Groot

Phase I Trial of 6-Hour Infusion of Glufosfamide, a New Alkylating Agent With Potentially Enhanced Selectivity for Tumors That Overexpress Transmembrane Glucose Transporters: A Study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group

Evangelos Briasoulis, Ian Judson, Nicholas Pavlidis et al. · Journal of Clinical Oncology · 2000 · 60 citations

Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide

W.W. ten Bokkel Huinink, IAM Mandjes, Y. Groot et al. · British Journal of Cancer · 1997 · 46 citations · Full text

Pharmacological Study, Medicine, Oral Etoposide +6

Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9

Howard L. McLeod, Marien Alet Graham, Steinar Aamdal et al. · European Journal of Cancer · 1996 · 28 citations

Therapeutic Drug Monitoring, Medicine, Bioanalysis +5

Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.

Ingmar Wolff, K Bench, Jos H. Beijnen et al. · PubMed · 1996 · 16 citations

Tumor Biology, Medicinal Chemistry, Consecutive Days +14

Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule

Ahmad Awada, Cornelis J. A. Punt, Martine Piccart et al. · British Journal of Cancer · 1999 · 16 citations · Full text